Tegatrabetan

Description: Tegatrabetan (BC2059) is a small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity. Target: Wnt/beta-catenin. Smiles: C[C@H]1C[C@@H](C)CN(C1)S(=O)(=O)c1ccc2C(=NO)c3ccc(cc3C(=NO)c2c1)S(=O)(=O)N1C[C@@H](C)C[C@@H](C)C1. References: Savvidou I, Khong T, Cuddihy A, et al. Beta-catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma[J]. Molecular Cancer Therapeutics, 2017, 16(9):molcanther.0624.2016.